name: | Eflapegrastim | |
ATC code: | L03AA19 | route: | subcutaneous |
compartments: | 2 | |
dosage: | 13.2 | mg |
volume of distribution: | 0.11 | L |
clearance: | 0.0272 | L/h/kg |
other parameters in model implementation |
Eflapegrastim is a long-acting, recombinant human granulocyte colony-stimulating factor (G-CSF) analog, conjugated to a human IgG4 Fc fragment via a polyethylene glycol linker. It is used for the reduction in the duration of severe neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. It is approved for use in the United States.
Population pharmacokinetics in adult cancer patients; healthy volunteers and patients with breast cancer following subcutaneous administration.